Sanders Morris Harris

Olatec Therapeutics is a biopharmaceutical company focused on developing safe, oral therapeutics that act as NLRP3 antagonists to treat and prevent a range of acute and chronic inflammatory diseases. These conditions, which are often mediated by Interleukin-1, include arthritis, heart failure, asthma, Alzheimer’s disease, multiple sclerosis, type-2 diabetes, melanoma, and breast cancers. The company's lead compound, dapansutrile, selectively targets the NLRP3 inflammasome, inhibiting the production of pro-inflammatory cytokines IL-1B and IL-18. With a team of experienced professionals and thought leaders in inflammation and immunology, Olatec aims to advance its proprietary pipeline of NLRP3 inhibitors to address significant unmet medical needs. The company operates in the United States and Europe, with offices in New York and the Netherlands.

- Jerini was founded in 1994 as a spin-off from the Medical Faculty (Charité) Humboldt University Berlin to commercialize the SPOT™ technology. The evolving SPOT™ platform was marketed as fee for service projects to pharmaceutical and biotech companies (1995 to 1999). The revenues generated supported the expansion of the company and its technology development. At this stage no venture capital was raised. Due to the expanding applications of its technology platform in drug discovery and proteomics Jerini began its transformation into a drug discovery company. - To support and accelerate the drug discovery transition Jerini raised Euro 4.6 million in January 2000 in a first financing round that included local investors IBB-Bet. GmbH, bmp AG and tbg. In 2001 the company converted to an AG (joint-stock company) and closed its second, private financing round raising Euro 20 million in November 2001. The investors in this round included an international group represented by TVM, 3i, Polytechnos and Sanders Morris and Harris. - In 2000 Jerini started creating the medicinal chemistry platform PepMed™ focusing on the identification of peptide lead structures addressing difficult protein targets and their subsequent systematic transformation into drug-like molecules. - In December 2001 Jerini started its first clinical trials with Icatibant, a peptidomimetic bradykinin receptor antagonist for the indication defined as end-stage liver cirrhosis.

Lombardi Software, Inc. is a provider of business process management (BPM) software and services based in Austin, Texas. Founded in 1999, the company offers a range of products including Teamworks 6, a BPM software suite designed to support process improvement applications, and Blueprint, a software-as-a-service solution that helps organizations map business processes, identify issues, and prioritize improvements. Additionally, Lombardi Software provides process documentation and workflow diagramming tools, as well as a variety of services such as process definition, deployment, on-demand assistance, and education. Their offerings also extend to on-site services, including process design, project management, and service-oriented architecture integration reviews. The company's clientele spans various sectors, including financial services, government, healthcare, insurance, life sciences, manufacturing, retail, and telecommunications.

Lombardi Software, Inc. is a provider of business process management (BPM) software and services based in Austin, Texas. Founded in 1999, the company offers a range of products including Teamworks 6, a BPM software suite designed to support process improvement applications, and Blueprint, a software-as-a-service solution that helps organizations map business processes, identify issues, and prioritize improvements. Additionally, Lombardi Software provides process documentation and workflow diagramming tools, as well as a variety of services such as process definition, deployment, on-demand assistance, and education. Their offerings also extend to on-site services, including process design, project management, and service-oriented architecture integration reviews. The company's clientele spans various sectors, including financial services, government, healthcare, insurance, life sciences, manufacturing, retail, and telecommunications.

IndX Software is an enterprise software firm specializing in operations intelligence solutions tailored for Fortune 2000 companies, particularly in the process manufacturing sector and their supply chains. The company's flagship product, XHQ, offers users a unified view of critical information necessary for real-time decision-making and performance management. By extracting and integrating data from various disparate backend systems, XHQ aggregates and manages content effectively, ensuring that relevant information is readily accessible to users. IndX Software focuses on the energy and manufacturing industries, providing essential tools to enhance operational efficiency and decision support in large industrial environments.

Direvo Industrial Biotechnology GmbH is a privately owned company based in Cologne, Germany, specializing in the development and marketing of biology-based products and processes for non-pharmaceutical applications. Founded in 2008, the company utilizes its expertise in enzymes, microbes, and process optimization to create bio-based solutions across various sectors, including clean energy, clean chemistry, and biomass conversion. Direvo offers a range of innovative platforms, such as the BluZy portfolio, designed for the grain ethanol industry, which includes products that enhance the nutritional value of bio-ethanol by-products and improve process efficiency in ethanol production. Additionally, the company provides the BluServ platform, focused on automated high-throughput screening for protein and strain engineering, and the BluCon technology platform, which converts non-food feedstocks into carbohydrates for fuel and chemical production. Direvo collaborates with global leaders in the industry to deliver customized solutions tailored to specific market needs.

Wayport Holdings is a provider of network-based guest services, specializing in the operation of WiFi hotspots for partners since its inception in 1998. The company focuses on delivering internet and business center services primarily to hotels, with a presence in locations such as Copenhagen, Denmark. By enhancing connectivity for guests, Wayport facilitates seamless online experiences in hospitality environments. The company has garnered support from prominent investors throughout its history.

Valera is a specialty pharmaceutical company concentrating on the development, acquisition and commercialization of products for the treatment of urological and endocrine conditions, diseases and disorders, including products that utilize our proprietary technology.

- Jerini was founded in 1994 as a spin-off from the Medical Faculty (Charité) Humboldt University Berlin to commercialize the SPOT™ technology. The evolving SPOT™ platform was marketed as fee for service projects to pharmaceutical and biotech companies (1995 to 1999). The revenues generated supported the expansion of the company and its technology development. At this stage no venture capital was raised. Due to the expanding applications of its technology platform in drug discovery and proteomics Jerini began its transformation into a drug discovery company. - To support and accelerate the drug discovery transition Jerini raised Euro 4.6 million in January 2000 in a first financing round that included local investors IBB-Bet. GmbH, bmp AG and tbg. In 2001 the company converted to an AG (joint-stock company) and closed its second, private financing round raising Euro 20 million in November 2001. The investors in this round included an international group represented by TVM, 3i, Polytechnos and Sanders Morris and Harris. - In 2000 Jerini started creating the medicinal chemistry platform PepMed™ focusing on the identification of peptide lead structures addressing difficult protein targets and their subsequent systematic transformation into drug-like molecules. - In December 2001 Jerini started its first clinical trials with Icatibant, a peptidomimetic bradykinin receptor antagonist for the indication defined as end-stage liver cirrhosis.

IndX Software is an enterprise software firm specializing in operations intelligence solutions tailored for Fortune 2000 companies, particularly in the process manufacturing sector and their supply chains. The company's flagship product, XHQ, offers users a unified view of critical information necessary for real-time decision-making and performance management. By extracting and integrating data from various disparate backend systems, XHQ aggregates and manages content effectively, ensuring that relevant information is readily accessible to users. IndX Software focuses on the energy and manufacturing industries, providing essential tools to enhance operational efficiency and decision support in large industrial environments.

Nuforia is an Internet professional services company resulting from the 1999 merger of communications.